New anemia drug may cut iron needs for kidney patients

NCT ID NCT07517744

Completed Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared two drugs—roxadustat and darbepoetin alfa—for treating anemia in 35 adults on hemodialysis. The goal was to see if roxadustat improves iron levels and reduces the need for IV iron. Researchers measured changes in iron profile, hemoglobin, and kidney function over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Roxadustat and darbepoetin alfa
What this could lead to: If successful, this could show that roxadustat improves iron use and reduces the need for IV iron in dialysis patients with anemia.
What could go wrong: This is a small, completed study with only 35 participants, so results may not apply to all patients. It compares two existing drugs, not a new breakthrough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates